ArticleCancer cell international2026
From heterogeneity to mechanism: a systems-level analysis pinpoints the S100A8/A9 axis in colorectal cancer.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe functional roles of the S100 protein family in colorectal cancer (CRC) are enigmatic, marked by widespread dysregulation but limited prognostic utility. This heterogeneity obscures their potential as therapeutic targets.
methodsWe employed a multi-omics strategy to deconstruct this complexity, integrating bulk transcriptomics (TCGA), large-scale single-cell RNA-seq atlases, and machine learning-based prioritization. Cell-type-specific expression patterns were contextualized using the spatial annotation of cell origins available within the Pan-GI Cell Atlas. Key findings were validated experimentally via qRT-PCR in a 30-patient cohort and functionally assessed using in vitro assays.
resultsWhile 17 S100 genes were differentially expressed in bulk tumor tissue, they lacked collective prognostic power. Single-cell analysis resolved this paradox, revealing that the expression of key alarmins S100A8 and S100A9 is not tumor-intrinsic but is highly concentrated in tumor-infiltrating myeloid cells. This myeloid-specific signature was associated with high-grade disease and progressively increased from polyps to tumors. We experimentally validated that S100A8 and S100A9 mRNA levels are significantly elevated in CRC tissues versus adjacent normal controls (S100A8, p = 0.004; S100A9, p = 0.012). Functionally, recombinant S100A8 and S100A9 acted as drivers of inflammation, directly inducing a pro-inflammatory cascade including NF-κB, IL-6, and IL-8 in CRC cells.
conclusionsOur findings clarify the S100 family's role in CRC, identifying the myeloid-derived S100A8 and S100A9 axis as a key amplifier of the pro-tumorigenic inflammatory microenvironment. This axis represents a critical nexus between innate immunity and carcinogenesis, offering a promising target for novel anti-inflammatory or immunomodulatory therapies in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.